Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ASND Ascendis Pharma A/S

Market Closed 10-09 16:00:00 EDT

229.23

+6.54

+2.94%

盘后229.23

+0.000.00%

19:30 EDT

High233.96	Low223.96	Vol815.74K
Open225.08	D1 Closing222.69	Amplitude4.49%
Mkt Cap15.17B	Tradable Cap15.02B	Total Shares66.19M
T/O186.89M	T/O Rate1.24%	Tradable Shares65.54M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ASND","market":"US","secType":"STK","nameCN":"Ascendis Pharma A/S","latestPrice":229.23,"timestamp":1791576000000,"preClose":222.69,"halted":0,"volume":815743,"hourTrading":{"tag":"盘后","latestPrice":229.23,"preClose":229.23,"latestTime":"19:30 EDT","volume":90402,"amount":20722855.6913,"timestamp":1791588606435,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.029368179981139664,"floatShares":65539518,"shares":66189926,"eps":13.1241,"marketStatus":"Market Closed","change":6.54,"latestTime":"10-09 16:00:00 EDT","open":225.08,"high":233.96,"low":223.955,"amount":186889331.6776,"amplitude":0.044928,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":13.1241,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":1,"adrRate":1,"listingDate":1422421200000,"exchange":"NASDAQ","adjPreClose":222.69,"preHourTrading":{"tag":"盘前","latestPrice":225,"preClose":222.69,"latestTime":"09:27 EDT","volume":200,"amount":45000,"timestamp":1791552470070,"change":2.31,"changeRate":0.010373,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":229.23,"preClose":229.23,"latestTime":"19:30 EDT","volume":90402,"amount":20722855.6913,"timestamp":1791588606435,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9570424735251243,"impliedVol":0.4517,"impliedVolPercentile":0.3745},"requestUrl":"/m/hq/s/ASND","defaultTab":"news","newsList":[{"id":"2674823468","title":"RBC Capital Sticks to Its Buy Rating for Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674823468","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674823468?lang=en_us&edition=fundamental","pubTime":"2026-10-09 09:47","pubTimestamp":1791510432,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Luca Issi maintained a Buy rating on Ascendis Pharma yesterday and set a price target of $290.00. Issi covers the Healthcare se...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-buy-rating-for-ascendis-pharma-asnd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-buy-rating-for-ascendis-pharma-asnd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673691580","title":"What Does Ascendis Pharma (ASND) Gain From Its CNP Patent Settlement?","url":"https://stock-news.laohu8.com/highlight/detail?id=2673691580","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673691580?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:26","pubTimestamp":1791325560,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (NasdaqGS:ASND) and BioMarin Pharmaceutical signed a worldwide settlement and license agreement covering C-type natriuretic peptide patents and products.\nThe deal resolves all ongoing litigation between the two drugmakers related to TransCon CNP, also known as navepegritide or Yuviwel.\nBioMarin granted Ascendis a non-exclusive, global license to develop and commercialize CNP-related therapies for all indications, with royalties to be paid.\nBeyond this CNP settlement and...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma/news/what-does-ascendis-pharma-asnd-gain-from-its-cnp-patent-sett","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma/news/what-does-ascendis-pharma-asnd-gain-from-its-cnp-patent-sett","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0320765992.SGD","MEDI","BK4585","ASND","LU0109394709.USD","LU0889565916.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673051652","title":"Ascendis Says Pooled PaTH Forward/PaTHway Data Show TransCon PTH Normalizes Bone Measures over 5 Years in Hypoparathyroidism","url":"https://stock-news.laohu8.com/highlight/detail?id=2673051652","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673051652?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:15","pubTimestamp":1791292546,"startTime":"0","endTime":"0","summary":"Ascendis says pooled PaTH Forward/PaTHway data show TransCon PTH normalizes bone measures over 5 years in hypoparathyroidismAscendis Pharma flagged new long-term pooled data for TransCon PTH in chroni","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDLbhZfGg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BGHQF748.EUR","SG9999014005.SGD","NDAQ","IE00BQXX3C00.GBP","LU0889565916.HKD","ASND","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","LU0320765992.SGD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BCDF","LU2210150020.SGD","BK4585","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","SG9999014039.USD","BK4588","IE00BN0W2W23.USD","LU0109394709.USD","SG9999014021.USD","MEDI","LU2210149790.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672782980","title":"BioMarin Signs Global Patent License Deal with Ascendis for TransCon CNP Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2672782980","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672782980?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:16","pubTimestamp":1790799414,"startTime":"0","endTime":"0","summary":"BioMarin signs global patent license deal with Ascendis for TransCon CNP productsBioMarin signed a settlement and license agreement with Ascendis covering TransCon CNP products, effective Aug. 28, 202","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL4xHDQC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4139","ASND","LU0320765992.SGD","LU0109394709.USD","MEDI","BMRN","IE0002270589.USD","IE00B7SZLL34.SGD","BK4585","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671270403","title":"Barclays Reaffirms Their Buy Rating on Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671270403","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671270403?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:25","pubTimestamp":1790760351,"startTime":"0","endTime":"0","summary":"In a report released today, Eliana Merle from Barclays maintained a Buy rating on Ascendis Pharma, with a price target of $329.00. According to Tip...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-buy-rating-on-ascendis-pharma-asnd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-buy-rating-on-ascendis-pharma-asnd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670237166","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ascendis Pharma (ASND), Lakefront Biotherapeutics (LKFT) and 10x Genomics (TXG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670237166","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670237166?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:30","pubTimestamp":1790598641,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ascendis Pharma (ASND), Lakefront Biotherapeutics ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-ascendis-pharma-asnd-lakefront-biotherapeutics-lkft-and-10x-genomics-txg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-ascendis-pharma-asnd-lakefront-biotherapeutics-lkft-and-10x-genomics-txg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0963586101.USD","BK4548","FMED","BK4137","BK4585","XBI","LU0109394709.USD","ARKG","BK4139","LU0029874061.USD","LU1861558580.USD","HCSG","BK4121","BK4588","BK4581","LU0889565916.HKD","LU0128526141.USD","ASND","MEDI","LABU","LU1861559042.SGD","LU0320765992.SGD","XLV","TXG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670235963","title":"Ascendis Pharma Price Target Maintained with a $300.00/Share by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2670235963","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670235963?lang=en_us&edition=fundamental","pubTime":"2026-09-28 17:56","pubTimestamp":1790589360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ASND/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4585","LU0320765992.SGD","ASND","MEDI","LU0109394709.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667979600","title":"Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ascendis Pharma (ASND) and Charles River Labs (CRL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667979600","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667979600?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:20","pubTimestamp":1789557614,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vertex Pharmaceuticals (VRTX), Ascendis Pharma (ASND...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vertex-pharmaceuticals-vrtx-ascendis-pharma-asnd-and-charles-river-labs-crl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vertex-pharmaceuticals-vrtx-ascendis-pharma-asnd-and-charles-river-labs-crl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2462157665.USD","LU1559883803.SGD","LU1674673428.USD","IDNA","BK4585","VERX","XBI","LU0390134368.USD","LU1093756325.SGD","XLV","ASND","TBXU","BK4588","IBB","LU1093756168.USD","LU1035775433.USD","SGXZ57979304.SGD","LU1069344957.HKD","IE0009355771.USD","LU0061475181.USD","IE00BZ9MQY76.HKD","LU2362541273.HKD","PBE","HCSG","BK4023","BBH","GNMX","BIB","LU0029874061.USD","CRL","LU2324357040.USD","LU2236285917.USD","LU2362540622.SGD","LU0889565916.HKD","LU0289739699.SGD","LU1430594728.SGD","BK4533","LABU","VRTX","LU0109394709.USD","BK4581","LU1585245621.USD","MEDI","IE00BJJMRZ35.SGD","LU0757428866.USD","IBBQ","IE00B894F039.SGD","LU2237438978.USD","LU1778281490.HKD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667626929","title":"Ascendis Pharma A/S Stock (ASND) Moved Down by 12.08% on Sep 15: What Signal Does It Send?","url":"https://stock-news.laohu8.com/highlight/detail?id=2667626929","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667626929?lang=en_us&edition=fundamental","pubTime":"2026-09-16 00:15","pubTimestamp":1789488922,"startTime":"0","endTime":"0","summary":"• Ascendis Pharma stock fell after terminating its collaboration agreement with Novo Nordisk.\n• Investors worry about independent funding and high expenses for obesity clinical programs.\n• The company reported an annual revenue of $854.80M and net loss.","market":"fut","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262169159-market-movers-asnd-20260915","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","BK4139","ASND","LU0889565916.HKD","MEDI","LU0109394709.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164371890","title":"Movement Alert｜Ascendis Pharma A/S Falls 12.23% in Regular Trading, Termination of Novo Nordisk Obesity Drug Collaboration Triggers Selloff","url":"https://stock-news.laohu8.com/highlight/detail?id=1164371890","media":"Market Focus","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164371890?lang=en_us&edition=fundamental","pubTime":"2026-09-16 00:13","pubTimestamp":1789488830,"startTime":"0","endTime":"0","summary":"On September 15, Ascendis Pharma A/S fell 12.23% in regular trading, trading at approximately $233.06 per share, with turnover of $3.0 billion — significantly underperforming the broader...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Ascendis Pharma Drops on Novo Nordisk Deal Termination","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667623077","title":"Ascendis Pharma Tumbles on Novo Nordisk Collab Termination","url":"https://stock-news.laohu8.com/highlight/detail?id=2667623077","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667623077?lang=en_us&edition=fundamental","pubTime":"2026-09-15 23:11","pubTimestamp":1789485062,"startTime":"0","endTime":"0","summary":"BUZZ-Ascendis Pharma tumbles on Novo Nordisk collab termination** Shares of Ascendis PharmaASND.Ofall 13.3% to $229.79** ASND said late on Monday it had ended its partnership with Danish drugmaker Novo NordiskNOVOb.CO** ASND regained all exclusive rights to its TransCon technology for metabolic and cardiovascular diseases** \"We see the repo as a clear positive and ultimately see better potential for value creation with the targets back in ASND’s hands given what had become slow progress moving TransCon Sema into the clinic, which still has yet to happen nearly two years after the collab was announced,\" J.P. Morgan analysts says** ASND partnered with Novo Nordisk in 2024 to develop long-acting obesity and diabetes treatments in a deal worth up to $285 mln** Both companies ended all ongoing financial obligations to each other** Separately, ASND announced a plan tobuy backup to $400 mln of its own shares** Including session's move, ASND up 8.8% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL4N457141:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","ASND","BK4585","LU0109394709.USD","LU0889565916.HKD","BK4139","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667628239","title":"Ascendis Pharma falls -12.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667628239","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667628239?lang=en_us&edition=fundamental","pubTime":"2026-09-15 22:05","pubTimestamp":1789481144,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) is down -12.1%, or -$32.14 to $232.78. Published first on TheFly – the ultimate source for real-time, market-moving breaking...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-falls-12-1-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-falls-12-1-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","BK4585","ASND","LU0889565916.HKD","BK4139","MEDI","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667647921","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2667647921","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667647921?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:56","pubTimestamp":1789477008,"startTime":"0","endTime":"0","summary":"Healthcare stocks were mixed pre-bell Tuesday, with the State Street Health Care Select Sector SPDR ETF  up 0.1% and the iShares Biotechnology ETF  0.5% lower.Ascendis Pharma  will regain exclusive rights to certain drug treatments for metabolic and cardiovascular diseases, including obesity, having terminated a 2024 collaboration deal with Novo Nordisk , the company said. Shares of Ascendis Pharma were down less than 3% premarket.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","NVOH","LU0109394709.USD","IE00BKVL7J92.USD","ASND","MEDI","BK4581","LU0154236417.USD","NVOC","XBI","LU1093756325.SGD","LU0320765992.SGD","PPH","NVOX","LU1093756168.USD","IE00BZ1G4Q59.USD","XLV","OZEM","BK4007","BK4139","LABU","THNR","BK4585","BK4532","NVO","IBB","BK4599","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667699622","title":"Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved","url":"https://stock-news.laohu8.com/highlight/detail?id=2667699622","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667699622?lang=en_us&edition=fundamental","pubTime":"2026-09-15 06:34","pubTimestamp":1789425240,"startTime":"0","endTime":"0","summary":"Ascendis Pharma regained exclusive rights to develop its TransCon technology to treat obesity after ending its partnership with Novo Nordisk.The Danish company said  Monday it can develop, manufacture","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","ASND","BK4139","MEDI","LU0109394709.USD","BK4585","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667869937","title":"Ascendis Pharma to regain rights to TransCon technology-based products","url":"https://stock-news.laohu8.com/highlight/detail?id=2667869937","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667869937?lang=en_us&edition=fundamental","pubTime":"2026-09-15 06:05","pubTimestamp":1789423516,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) announced that it will regain the exclusive rights to develop, manufacture, and commercialize TransCon technology-based prod...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-to-regain-rights-to-transcon-technology-based-products-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-to-regain-rights-to-transcon-technology-based-products-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","MEDI","LU0889565916.HKD","BK4139","ASND","BK4585","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667699340","title":"Ascendis Pharma announces $400M share repurchase plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2667699340","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667699340?lang=en_us&edition=fundamental","pubTime":"2026-09-15 06:05","pubTimestamp":1789423508,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) announced that its Board of Directors has authorized the company to repurchase up to $400M of the company’s ordinary shares....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-announces-400m-share-repurchase-plan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-announces-400m-share-repurchase-plan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","MEDI","BK4585","BK4139","ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667967396","title":"Ascendis Pharma a/S - to Regain Exclusive Rights to Transcon Technology in Metabolic and Cardiovascular Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2667967396","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667967396?lang=en_us&edition=fundamental","pubTime":"2026-09-15 06:01","pubTimestamp":1789423303,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nFWN4560FC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ASND","LU0109394709.USD","BK4585","MEDI","BK4139","LU0320765992.SGD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667783696","title":"Press Release: Ascendis Announces Planned $400 Million Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2667783696","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667783696?lang=en_us&edition=fundamental","pubTime":"2026-09-15 06:00","pubTimestamp":1789423200,"startTime":"0","endTime":"0","summary":"COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASND","LU0889565916.HKD","MEDI","BK4139","BK4585","BK4022","R","BK4232","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666057530","title":"Ascendis Pharma SVP & PAO Mads Bodenhoff Disposes of 3,000 Common Shares Worth $810,570","url":"https://stock-news.laohu8.com/highlight/detail?id=2666057530","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666057530?lang=en_us&edition=fundamental","pubTime":"2026-09-10 05:05","pubTimestamp":1788987910,"startTime":"0","endTime":"0","summary":"Ascendis Pharma SVP & PAO Mads Bodenhoff disposes of 3,000 common shares worth $810,570Ascendis Pharma A/S SVP and principal accounting officer Mads Bodenhoff sold 3,000 ordinary shares on Sept. 8, 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL5WjqxV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Ascendis Pharma SVP & PAO Mads Bodenhoff Disposes of 3,000 Common Shares Worth $810,570","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0889565916.HKD","ASND","BK4585","MEDI","LU0320765992.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666530812","title":"Ascendis Pharma announces data from reACHin Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666530812","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666530812?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:12","pubTimestamp":1788984725,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) announced Week 52 data from the open-label sentinel cohort portion of the reACHin Trial showing that treatment with once-wee...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-announces-data-from-reachin-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-announces-data-from-reachin-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASND","BK4139","MEDI","LU0889565916.HKD","LU0109394709.USD","BK4585","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascendispharma.com","stockEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.1211},{"period":"3month","weight":-0.1524},{"period":"6month","weight":-0.042},{"period":"1year","weight":0.0673},{"period":"ytd","weight":0.075}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.0313},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1417}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.031281},{"month":2,"riseRate":0.583333,"avgChangeRate":0.050705},{"month":3,"riseRate":0.416667,"avgChangeRate":0.030446},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.031037},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.005122},{"month":6,"riseRate":0.666667,"avgChangeRate":0.035016},{"month":7,"riseRate":0.583333,"avgChangeRate":-0.006819},{"month":8,"riseRate":0.75,"avgChangeRate":0.084399},{"month":9,"riseRate":0.583333,"avgChangeRate":0.025323},{"month":10,"riseRate":0.5,"avgChangeRate":-0.00848},{"month":11,"riseRate":0.818182,"avgChangeRate":0.047363},{"month":12,"riseRate":0.545455,"avgChangeRate":0.041981}],"exchange":"NASDAQ","name":"Ascendis Pharma A/S","nameEN":"Ascendis Pharma A/S","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ascendis Pharma A/S,ASND,Ascendis Pharma A/S股票,Ascendis Pharma A/S股票老虎,Ascendis Pharma A/S股票老虎国际,Ascendis Pharma A/S行情,Ascendis Pharma A/S股票行情,Ascendis Pharma A/S股价,Ascendis Pharma A/S股市,Ascendis Pharma A/S股票价格,Ascendis Pharma A/S股票交易,Ascendis Pharma A/S股票购买,Ascendis Pharma A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction